<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0712222986
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZIDRONIC 4 mg/5 ml Vial
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ZOLEDRONIC ACID
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.8
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        713.60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hikma Farmaceutica" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hikma Farmaceutica
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M05BA08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance in Zidronic is zoledronic acid, which belongs to a group of substances called bisphosphonates. Zoledronic acid works by attaching itself to the bone and slowing down the rate of bone change.</p><p><strong>It is used:</strong></p><ul><li>To prevent bone complications, e.g. fractures, in adult patients with bone metastases (spread of cancer from primary site to the bone).</li><li>To reduce the amount of calcium in the blood in adult patients where it is too high due to the presence of a tumour. Tumours can accelerate normal bone change in such a way that the release of calcium from bone is increased. This condition is known as tumour-induced hypercalcaemia (TIH).</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow carefully all instructions given to you by your doctor.</p><p>Your doctor will carry out blood tests before you start treatment with Zidronic and will check your response to treatment at regular intervals.</p><p>&nbsp;<strong>You should not be given </strong><strong>Zidronic</strong><strong>: </strong></p><ul><li>If you are breast-feeding.</li><li>If you are allergic to zoledronic acid, another bisphosphonate (the group of substances to which zoledronic acid belongs), or any of the other ingredients of this medicine (listed in section 6).</li></ul><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor before you are given Zidronic:</p><ul><li>If you have or have had a kidney problem.</li><li>If you have or have had pain, swelling or numbness of the jaw, a feeling of heaviness in the jaw or loosening of a tooth. Your doctor may recommend a dental examination before you start treatment with Zidronic.</li><li>If you are having dental treatment or are due to undergo dental surgery, tell your dentist that you are being treated with Zidronic and inform your doctor about your dental treatment.</li></ul><p>While being treated with Zidronic, you should maintain good oral hygiene (including regular teeth brushing) and receive routine dental check-ups.</p><p>Contact your doctor and dentist immediately if you experience any problems with your mouth or teeth such as loose teeth, pain or swelling, or non-healing of sores or discharge, as these could be signs of a condition called osteonecrosis of the jaw.</p><p>Patients who are undergoing chemotherapy and/or radiotherapy, who are taking steroids, who are undergoing dental surgery, who do not receive routine dental care, who have gum disease, who are smokers, or who were previously treated with a bisphosphonate (used to treat or prevent bone disorders) may have a higher risk of developing osteonecrosis of the jaw.</p><p>Reduced levels of calcium in the blood (hypocalcaemia), sometimes leading to muscle cramps, dry skin, burning sensation, have been reported in patients treated with zoledronic acid. Irregular heart beat (cardiac arrhythmia), seizures, spasm and twitching (tetany) have been reported as secondary to severe hypocalcaemia. In some instances, the hypocalcaemia may be life-threatening. If any of these apply to you, tell your doctor straight away. If you have pre-existing hypocalcaemia, it must be corrected before initiating the first dose of Zidronic. You will be given adequate calcium and vitamin D supplements.</p><p><strong>Patients aged 65 years and over </strong></p><p>Zidronic can be given to people aged 65 years and over. There is no evidence to suggest that any extra precautions are needed.</p><p><strong>Children and adolescents</strong></p><p>Zidronic is not recommended for use in adolescents and children below the age of 18 years.</p><p><strong>Other medicines and Zidronic </strong></p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines. It is especially important that you tell your doctor if you are also taking:</p><ul><li>Aminoglycosides (medicines used to treat severe infections), calcitonin (a type of medicine used to treat post-menopausal osteoporosis and hypercalcaemia), loop diuretics (a type of medicine to treat high blood pressure or oedema) or other calcium-lowering medicines, since the combination of these with bisphosphonates may cause the calcium level in the blood to become too low.</li><li>Thalidomide (a medicine used to treat a certain type of blood cancer involving the bone) or any other medicines which may harm your kidneys.</li><li>Other medicines that also contains zoledronic acid and is used to treat osteoporosis and other non-cancer diseases of the bone), or any other bisphosphonate, since the combined effects of these medicines taken together with zoledronic acid are unknown.</li><li>Anti-angiogenic medicines (used to treat cancer), since the combination of these with zoledronic acid has been associated with an increased risk of osteonecrosis of the jaw (ONJ).</li></ul><p><strong>Pregnancy and breast-feeding</strong></p><p>You should not be given Zidronic if you are pregnant. Tell your doctor if you are or think that you may be pregnant.</p><p>You must not be given Zidronic if you are breast-feeding.</p><p>Ask your doctor for advice before taking any medicine while you are pregnant or breast-feeding.</p><p><strong>Driving and using machines </strong></p><p>There have been very rare cases of drowsiness and sleepiness with the use of zoledronic acid. You should therefore be careful when driving, using machinery or performing other tasks that need full attention.</p><p><strong>Zidronic</strong><strong> contains sodium</strong></p><p>Zidronic contains sodium. Each 5 ml of Zidronic 4 mg/5 ml Concentrate for Solution for Infusion contains 6.417 mg sodium. This medicine contains less than 1 mmol sodium (23 mg) per 5 ml, that is to say essentially &lsquo;sodium-free&rsquo;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Zidronic must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein.</li><li>Your doctor will recommend that you drink enough water before each treatment to help prevent dehydration.</li><li>Carefully follow all the other instructions given to you by your doctor, pharmacist or nurse.</li></ul><p><em>How much </em><em>Zidronic</em><em> is given </em></p><ul><li>The usual single dose given is 4 mg.</li><li>If you have a kidney problem, your doctor will give you a lower dose depending on the severity of your kidney problem.</li></ul><p><em>How often </em><em>Zidronic</em><em> is given</em></p><ul><li>If you are being treated for the prevention of bone complications due to bone metastases, you will be given one infusion of Zidronic every three to four weeks.</li><li>If you are being treated to reduce the amount of calcium in your blood, you will normally only be given one infusion of Zidronic.</li></ul><p><em>How </em><em>Zidronic</em><em> is given</em></p><ul><li>&middot;Zidronic is given as a drip (infusion) into a vein which should take at least 15 minutes and should be administered as a single intravenous solution in a separate infusion line.</li></ul><p>Patients whose blood calcium levels are not too high will also be prescribed calcium and vitamin D supplements to be taken each day.</p><p><strong>If you are given more </strong><strong>Zidronic</strong><strong> than you should be</strong></p><p>If you have received doses higher than those recommended, you must be carefully monitored by your doctor. This is because you may develop serum electrolyte abnormalities (e.g. abnormal levels of calcium, phosphorus and magnesium) and/or changes in kidney function, including severe kidney impairment. If your level of calcium falls too low, you may have to be given supplemental calcium by infusion</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The most common ones are usually mild and will probably disappear after a short time.</p><p><strong><em>Tell your doctor about any of the following serious side effects straight away: </em></strong></p><p><strong>Common (may affect up to 1 in 10 people):</strong></p><ul><li>Severe kidney impairment (will normally be determined by your doctor with certain specific blood tests).</li><li>Low level of calcium in the blood.</li></ul><p><strong>Uncommon (may affect up to 1 in 100 people): </strong></p><ul><li>Pain in the mouth, teeth and/or jaw, swelling or non-healing sores inside the mouth or jaw discharge, numbness or a feeling of heaviness in the jaw or loosening of a tooth. These could be signs of bone damage in the jaw (osteonecrosis). Tell your doctor and dentist immediately if you experience such symptoms while being treated with zoledronic acid or after stopping treatment.</li><li>Irregular heart rhythm (atrial fibrillation) has been seen in patients receiving zoledronic acid for postmenopausal osteoporosis. It is currently unclear whether zoledronic acid causes this irregular heart rhythm but you should report it to your doctor if you experience such symptoms after you have received zoledronic acid.</li><li>Severe allergic reaction: shortness of breath, swelling mainly of the face and throat.</li></ul><p><strong>Rare (may affect up to 1 in 1,000 people): </strong></p><ul><li>As a consequence of low calcium values: irregular heart beat (cardiac arrhythmia; secondary to hypocalcaemia).</li><li>A kidney function disorder called Fanconi syndrome (will normally be determined by your doctor with certain urine tests).</li></ul><p><strong>Very rare (may affect up to 1 in 10,000 people):</strong></p><ul><li>As a consequence of low calcium values: seizures, numbness and tetany (secondary to hypocalcaemia).</li><li>Talk to your doctor if you have ear pain, discharge from the ear, and/or an ear infection. These could be signs of bone damage in the ear.</li><li>Osteonecrosis has also very rarely been seen occurring with other bones than the jaw, especially the hip or thigh. Tell your doctor immediately if you experience symptoms such as new onset or worsening of aches, pain or stiffness while being treated with zoledronic acid or after stopping treatment.</li></ul><p><strong><em>Tell your doctor about any of the following side effects as soon as possible: </em></strong></p><p><strong>Very common (may affect more than 1 in 10 people):</strong></p><ul><li>Low level of phosphate in the blood.</li></ul><p><strong>Common (may affect up to 1 in 10 people): </strong></p><ul><li>Headache and a flu-like syndrome consisting of fever, fatigue, weakness, drowsiness, chills and bone, joint and/or muscle ache. In most cases no specific treatment is required, and the symptoms disappear after a short time (couple of hours or days).</li><li>Gastrointestinal reactions such as nausea and vomiting as well as loss of appetite.</li><li>Conjunctivitis.</li><li>Low level of red blood cells (anaemia).</li></ul><p>&nbsp;</p><p><strong>Uncommon (may affect up to 1 in 100 people):</strong></p><ul><li>Hypersensitivity reactions.</li><li>Low blood pressure.</li><li>Chest pain.</li><li>Skin reactions (redness and swelling) at the infusion site, rash, itching.</li><li>High blood pressure, shortness of breath, dizziness, anxiety, sleep disturbances, taste disturbances, trembling, tingling or numbness of the hands or feet, diarrhea, constipation, abdominal pain, dry mouth.</li><li>Low counts of white blood cells and blood platelets.</li><li>Low level of magnesium and potassium in the blood. Your doctor will monitor this and take any necessary measures.</li><li>Weight increase.</li><li>Increased sweating.</li><li>Sleepiness.</li><li>Blurred vision, tearing of the eye, eye sensitivity to light.</li><li>Sudden coldness with fainting, limpness or collapse.</li><li>Difficulty in breathing with wheezing or coughing.</li><li>Urticaria.</li></ul><p><strong>Rare (may affect up to 1 in 1,000 people):</strong></p><ul><li>Slow heart beat.</li><li>Confusion.</li><li>Unusual fracture of the thigh bone particularly in patients on long-term treatment for osteoporosis may occur rarely. Contact your doctor if you experience pain, weakness or discomfort in your thigh, hip or groin as this may be an early indication of a possible fracture of the thigh bone.</li><li>Interstitial lung disease (inflammation of the tissue around the air sacks of the lungs).</li><li>Flu-like symptoms including arthritis and joint swelling.</li><li>Painful redness and/or swelling of the eye.</li></ul><p><strong>Very rare (may affect up to 1 in 10,000 people):</strong></p><ul><li>&middot;&nbsp;&nbsp;&nbsp; Fainting due to low blood pressure.</li><li>&middot;&nbsp;&nbsp;&nbsp; Severe bone, joint and/or muscle pain, occasionally incapacitating</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30&deg;C.</p><p>Store in the original package.</p><p>After dilution: the diluted solution for infusion should be used immediately in order to avoid microbial contamination. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2-8&deg;C.</p><p>The refrigerated solution should then be equilibrated to room temperature prior to administration.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is zoledronic acid monohydrate.</p><p>Each 5 ml of Zidronic 4 mg/5 ml Concentrate for Solution for Infusion contains 4.264 mg zoledronic acid monohydrate equivalent to 4 mg zoledronic acid anhydrous.</p><p>The other ingredients are mannitol, sodium citrate and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Zidronic 4 mg/5 ml Concentrate for Solution for Infusion is a clear and colourless solution in 5 ml type I clear glass vials sealed with butyl grey rubber stoppers and blue aluminum flip-off caps.

Pack size: 1 Vial (5 ml). 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong></p><p>Jazeera Pharmaceutical Industries</p><p>Al-Kharj Road</p><p>P.O. Box 106229</p><p>Riyadh 11666, Saudi Arabia</p><p>Tel: + (966-11) 8107023, + (966-11) 2142472</p><p>Fax: + (966-11) 2078170</p><p>e-mail: SAPV@hikma.com</p><p><strong>Manufacturer</strong></p><p>Hikma Farmaceutica (Portugal), S.A.</p><p>Estrada do Rio Da M&oacute;,</p><p>n.&deg;8, 8A e 8B, Ferven&ccedil;a</p><p>2705-906 Terrugem</p><p>Sintra, Portugal</p><p>Tel: + (351-2) 19608410</p><p>Fax: + (351-2) 19615102<br /><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.<strong style="text-align:unset">&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 01/2024; version number SA2.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">المادة الفعّالة في زيدرونيك هي حمض الزوليدرونيك والذي ينتمي إلى مجموعة من المواد تدعى بيسفوسفونات. يعمل حمض الزوليدرونيك عن طريق الارتباط بالعظام وإبطاء معدّل تغير شكل العظام.</p><p dir="RTL"><strong>ويستخدم لـ:</strong></p><ul dir="rtl"><li>منع مضاعفات العظام، مثل الكسور، لدى المرضى البالغين المصابين بالنقائل العظمية (انتشار السرطان من الموضع الأولي إلى العظام).</li><li>تقليل كمية الكالسيوم في الدم لدى المرضى البالغين الذين يعانون من ارتفاع نسبته بصورة أكثر من اللازم بسبب وجود ورم. يمكن أن تسرّع الأورام من تغير شكل العظام الطبيعية بحيث يزداد خروج الكالسيوم من العظام. وهذه الحالة تعرف باسم فرط كالسيوم الدم بسبب الورم</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اتبع جميع التعليمات التي أوصاك بها طبيبك بعناية.</p><p dir="RTL">سيجري لك طبيبك فحوصات للدم قبل بدء العلاج باستخدام زيدرونيك وسيفحص استجابتك للعلاج على فترات منتظمة.</p><p dir="RTL">&nbsp;<strong>يجب عدم إعطائك زيدرونيك في الحالات التالية: </strong></p><ul dir="rtl"><li>إذا كنتِ ترضعين طبيعياً.</li><li>إذا كنت تعاني من حساسية تجاه حمض الزوليدرونيك أو أي مادة أخرى من البيسفوسفونات (مجموعة مواد ينتمي إليها حمض الزوليدرونيك) أو أي مواد أخرى مستخدمة في التركيبة التصنيعية لزوليدرونيك (المذكورة في القسم 6).</li></ul><p dir="RTL"><strong>الاحتياطات والتحذيرات </strong></p><p dir="RTL">تحدث مع طبيبك قبل إعطائك زيدرونيك في الحالات التالية:</p><ul dir="rtl"><li>إذا كنت تعاني الآن أو سابقاً من مشكلة في الكلى.</li><li>إذا كنت تعاني الآن أو في السابق من ألم أو تورم أو تنميل في الفك أو شعور بثقل في الفك أو تخلخل أحد الأسنان. قد يوصيك طبيبك بإجراء فحص للأسنان قبل بدء العلاج بزيدرونيك</li><li>إذا كنت تأخذ علاجاً للأسنان أو من المقرر أن تخضع لجراحة في الأسنان، أخبر طبيب الأسنان بأنك تُعالج باستخدام زيدرونيك وأخبر طبيبك عن العلاج الذي تأخذه للأسنان.</li></ul><p dir="RTL">أثناء العلاج بزيدرونيك، يجب عليك الحفاظ على نظافة الفم جيداً (بما في ذلك تفريش الأسنان بانتظام) والخضوع لفحوصات روتينية للأسنان.</p><p dir="RTL">اتصل على طبيبك وطبيب الأسنان المتابع لحالتك على الفور إذا عانيت من أي مشاكل في فمك أو الأسنان مثل خلخلة الأسنان، ألم أو تورم أو عدم التعافي من التقرحات أو الإفرازات، نظراً إلى أن ذلك يمكن أن يكون علامات لحالة تسمى النخر في عظام الفك.</p><p dir="RTL">قد يكون المرضى الذين يخضعون لعلاج كيميائي وإشعاعي أو أحدهما أو الذين يأخذون الستيرويدات أو الذين يخضعون لجراحة الأسنان أو الذين لا يتلقون الرعاية الروتينية للأسنان، أو المصابين بأمراض اللثة، أو المدخنين أو الذين سبق لهم العلاج باستخدام بيسفوسفونات (المستخدم في علاج أو منع اضطرابات العظام) أكثر عرضة للإصابة بالنخر في عظام الفك.</p><p dir="RTL">تم الإبلاغ عن انخفاض مستويات الكالسيوم في الدم (نقص كالسيوم الدم)، يؤدي أحياناً إلى تقلصات عضلية، جفاف الجلد، إحساس بالحرقان، لدى المرضى الذين يعالجون بحمض الزوليدرونيك. تم الإبلاغ عن عدم انتظام في نبضات القلب (اضطراب النظم القلبي) ونوبات صرع وتشنجات ونفضان (تكزز) باعتبارها أعراضاً ثانويةً للنقص الشديد لكالسيوم الدم. في بعض الحالات، قد يكون نقص كالسيوم الدم مُهدّداً للحياة. أخبر طبيبك على الفور إذا كان ينطبق عليك أي من ذلك. إذا كنت تعاني من نقص كالسيوم الدم الموجود مسبقاً، فيجب العلاج منه قبل بدء أخذ أول جرعة من زيدرونيك. سيتم إعطاؤك مكملات فيتامين د والكالسيوم بصورة كافية.</p><p dir="RTL"><strong>المرضى البالغون من العمر 65 عاماً فأكثر&nbsp; </strong></p><p dir="RTL">يمكن إعطاء زيدرونيك للأشخاص البالغين من العمر 65 عاماً فأكثر. لا يوجد دليل يشير إلى وجود حاجة إلى أي احتياطات إضافية.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يُوصى باستخدام زيدرونيك لدى المراهقين والأطفال الذين تقل أعمارهم عن 18 عاماً.</p><p dir="RTL"><strong>الأدوية الأخرى وزيدرونيك </strong></p><p dir="RTL">أخبر طبيبك إذا كنت تأخذ، أخذت مؤخراً، أو قد تأخذ أي أدوية أخرى. من المهم بشكل خاص أن تبلغ طبيبك إذا كنت تأخذ أيضاً ما يلي:</p><ul dir="rtl"><li>أمينوغليكوزيدات (الأدوية المستخدمة لعلاج حالات العدوى الشديدة) أو كالسيتونين (نوع من الدواء المستخدم في علاج هشاشة العظام بعد انقطاع الطمث وفرط كالسيوم الدم) أو مدرات البول العروية (نوع من الدواء لعلاج ارتفاع ضغط الدم أو الوذمة) أو أدوية أخرى لخفض الكالسيوم، لأن تناول هذه الأدوية مع بيسفوسفونات قد يسبب انخفاضاً حاداً لمستوى الكالسيوم في الدم.</li><li>ثاليدومايد (دواء يستخدم في علاج نوع معين من سرطان الدم يتضمن العظام) أو أي أدوية أخرى قد تسبب ضرراً للكليتين.</li><li>أي أدوية أخرى تحتوي على حمض الزوليدرونيك والمستخدم في علاج هشاشة العظام وأمراض العظام الأخرى غير السرطانية أو أي مواد أخرى من بيسفوسفونات، نظراً إلى أن التأثيرات المشتركة لأخذ هذه الأدوية مع حمض الزوليدرونيك غير معروفة.</li><li>الأدوية المضادة لتولد الأوعية (المستخدمة في علاج السرطان)، لأن تناول هذه الأدوية مع حمض الزوليدرونيك يرتبط بزيادة خطر الإصابة بالنخر في عظام الفك.</li></ul><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">يجب عدم إعطائكِ زيدرونيك إذا كنتِ حاملاً. أبلغي طبيبكِ إذا كنتِ حاملاً أو تعتقدين بأنكِ حاملاً.</p><p dir="RTL">يجب عدم إعطائكِ زيدرونيك إذا كنتِ تُرضعين طبيعياً.</p><p dir="RTL">يرجى استشارة طبيبكِ قبل أخذ أي دواء إذا كنتِ حاملاً أو مرضعاً.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong> <strong>&nbsp;</strong></p><p dir="RTL">كانت هناك حالات نادرة للغاية تشمل الخمول والنعاس مع استخدام حمض الزوليدرونيك. لذلك يجب أن تكون حذراً عند القيادة أو استخدام الآلات أو أداء مهام أخرى تحتاج إلى انتباه كامل.</p><p dir="RTL"><strong>يحتوي زيدرونيك على الصوديوم</strong></p><p dir="RTL">يحتوي زيدرونيك على الصوديوم. يحتوي كل 5 مللتر من زيدرونيك 4 ملغم/5 مللتر مركز للتخفيف للتسريب على 6,417 &nbsp;ملغم صوديوم. يحتوي هذا الدواء على أقل من 1 ملمول صوديوم (23 ملغم) لكل 5 مللتر، بمعنى أنه &rsquo;خالٍ من الصوديوم&lsquo; بشكل أساسي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul dir="rtl"><li>يجب عدم إعطاء زيدرونيك إلا بواسطة أخصائيي الرعاية الصحية المدربين على إعطاء بيسفوسفونات بالوريد.</li><li>سيوصيك طبيبك بشرب كمية كافية من المياه قبل أي علاج للمساعدة على منع الجفاف.</li><li>اتبع جميع التعليمات الأخرى التي أوصاك بها طبيبك، الصيدلي أو الممرض بعناية.</li></ul><p dir="RTL"><em>الكمية المُعطاة من </em><em>زيدرونيك </em></p><ul dir="rtl"><li>الجرعة الواحدة المعتادة هي 4 ملغم.</li><li>إذا كنت تعاني من مشكلة في الكلى، سيعطيك طبيبك جرعة أقل وفقاً لشدة مشكلة الكلية لديك.</li></ul><p dir="RTL"><em>عدد مرات إعطاء </em><em>زيدرونيك </em>&nbsp;</p><ul dir="rtl"><li>إذا كنت تخضع لعلاج من أجل منع مضاعفات العظام بسبب النقائل العظمية، فسيتم إعطاؤك جرعة تسريب واحدة من زيدرونيك كل فترة تتراوح من ثلاثة إلى أربعة أسابيع.</li><li>إذا كنت تتعالج لتقليل كمية الكالسيوم في الدم، سيتم إعطاؤك عادةً جرعة تسريب واحدة من زيدرونيك.</li></ul><p dir="RTL"><em>طريقة إعطاء </em><em>زيدرونيك</em></p><ul dir="rtl"><li>يتم إعطاء زيدرونيك عن طريق التقطير (التسريب) في الوريد، ويجب أن يستغرق 15 دقيقة على الأقل ويجب إعطاؤه على شكل محلول وريدي واحد من خلال أنبوب تسريب مستقل.</li></ul><p dir="RTL">سيتم أيضاً وصف مكملات فيتامين د وكالسيوم ليتم أخذها كل يوم للمرضى الذين لا يوجد لديهم ارتفاع في مستويات الكالسيوم في الدم بشكل كبير.</p><p dir="RTL"><strong>إذا تم إعطاؤك </strong><strong>زيدرونيك أكثر من اللازم</strong></p><p dir="RTL">إذا تلقيت جرعات أكثر من الحد الموصى به، فيجب أن يتابعك طبيبك بعناية. وذلك لأنك قد تكون مصاباً باختلال الكهارل في مصل الدم (مستويات غير طبيعية للكالسيوم والفوسفور والمغنيسيوم على سبيل المثال) و/أو تغيرات في وظائف الكلى، بما في ذلك الاختلال الشديد في وظائف الكلى. إذا انخفض مستوى الكالسيوم لديك بدرجة كبيرة، فقد تضطر إلى أخذ مكملات الكالسيوم عن طريق التسريب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبيةً، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء. تعتبر أكثر الآثار الجانبية شيوعاً طفيفة ومن المحتمل أن تختفي بعد فترة وجيزة.</p><p dir="RTL"><strong><em>أبلغ طبيبك على الفور بشأن أي من الآثار الجانبية الخطيرة التالية: </em></strong></p><p dir="RTL"><strong>شائعة (قد تؤثر فيما يصل إلى شخص من بين كل 10 أشخاص):</strong></p><ul dir="rtl"><li>الاختلال الكلوي الشديد (سيحدده طبيبك عادةً عن طريق إجراء فحوصات دم محددة معينة).</li><li>انخفاض مستوى الكالسيوم في الدم.</li></ul><p dir="RTL"><strong>غير شائعة (قد تؤثر فيما يصل إلى شخص من بين كل 100 شخص): </strong></p><ul dir="rtl"><li>ألم في الفم، الأسنان و/أو الفك، تورم أو عدم التعافي من التقرحات داخل الفم أو إفرازات الفك، تنميل أو شعور بثقل في الفك، أو تخلخل أحد الأسنان. يمكن أن تكون هذه علامات تضرر عظام الفك (النخر العظمي). أخبر طبيبك وطبيب الأسنان المتابع لحالتك على الفور، إذا عانيت من مثل هذه الأعراض أثناء العلاج باستخدام حمض الزوليدرونيك أو بعد التوقف عن العلاج.</li><li>تمت ملاحظة اضطراب في نظم القلب (الرجفان الأذيني) لدى المرضى الذين يتلقون حمض الزوليدرونيك لعلاج هشاشة العظام بعد انقطاع الطمث. ليس من الواضح في الوقت الحالي إذا ما كان حمض الزوليدرونيك يسبب عدم انتظام نظم القلب لكن يجب عليك إبلاغ طبيبك بذلك إذا عانيت من مثل هذه الأعراض بعد تلقي حمض الزوليدرونيك.</li><li>رد فعل تحسسي شديد: ضيق التنفس وتورم في الوجه والحلق بشكل أساسي.</li></ul><p dir="RTL"><strong>نادرة (قد تؤثر فيما يصل إلى شخص من بين كل 1000 شخص): </strong></p><ul dir="rtl"><li>نتيجة لانخفاض قيم الكالسيوم: عدم انتظام نبضات القلب (اضطراب النظم القلبي، عرض ثانوي لنقص كالسيوم الدم).</li><li>اضطراب وظائف الكلى يسمى متلازمة فانكوني (سيحدده طبيبك من خلال اختبارات بول معينة).</li></ul><p dir="RTL"><strong>نادرة جداً (قد تؤثر على ما يصل إلى 1 من بين كل 10,000 شخص):</strong></p><ul dir="rtl"><li>نتيجة لانخفاض قيم الكالسيوم: نوبات صرع وتنميل وتكزز (عرض ثانوي لنقص كالسيوم الدم).</li><li>تحدث إلى طبيبك إذا عانيت من ألم في الأذن وخروج إفرازات من الأذن و/أو عدوى الأذن. يمكن أن تكون هذه علامات تضرر العظام في الأذن.</li><li>من النادر جداً ملاحظة حدوث النخر العظمي مع عظام أخرى غير الفك، خصوصاً الورك أو الفخذ. أخبر طبيبك فوراً إذا كنت تعاني من أعراض مثل وجع جديد أو متفاقم أو ألم أو تيبس أثناء العلاج بحمض الزوليدرونيك أو بعد التوقف عن العلاج.</li></ul><p dir="RTL"><strong><em>أبلغ طبيبك عن أي من الآثار الجانبية التالية بأسرع ما يمكن: </em></strong></p><p dir="RTL"><strong>شائعة جداً (قد تؤثر في أكثر من شخص من بين كل 10 أشخاص):</strong></p><ul dir="rtl"><li>انخفاض مستوى الفوسفات في الدم.</li></ul><p dir="RTL"><strong>شائعة (قد تؤثر فيما يصل إلى شخص من بين كل 10 أشخاص): </strong></p><ul dir="rtl"><li>الصداع ومتلازمة شبيهة بالإنفلونزا تشمل حمّى وإجهاد وضعف وخمول وقشعريرة ووجع العظام والمفاصل و/أو العضلات. لا يلزم علاج محدد في أغلب الحالات حيث تختفي الأعراض بعد فترة وجيزة (بضع ساعات أو أيام).</li><li>تفاعلات مَعِدية معوية مثل غثيان وقيء بالإضافة إلى فقدان الشهية.</li><li>التهاب الملتحمة.</li><li>انخفاض مستوى خلايا الدم الحمراء (فقر الدم).</li></ul><p dir="RTL"><strong>غير شائعة (قد تؤثر فيما يصل إلى شخص من بين كل 100 شخص):</strong></p><ul dir="rtl"><li>ردود فعل فرط الحساسية.</li><li>انخفاض ضغط الدم.</li><li>ألم في الصدر.</li><li>ردود فعل جلدية (احمرار وتورم) عند موضع التسريب وطفح جلدي وحكة.</li><li>ارتفاع ضغط الدم، ضيق التنفس، دوخة، قلق، اضطرابات النوم، اضطرابات في حاسة التذوق، ارتجاف، وخز، أو تنميل اليدين أو القدمين، إسهال، إمساك، ألم في البطن، أو جفاف في الفم.</li><li>انخفاض عدد خلايا الدم البيضاء والصفائح الدموية.</li><li>انخفاض مستوى المغنسيوم والبوتاسيوم في الدم. سيراقب طبيبك هذا الوضع وسيتخذ أي تدابير ضرورية.</li><li>زيادة الوزن.</li><li>زيادة التعرق.</li><li>النعاس.</li><li>تشوش الرؤية أو سيلان دموع العينين أو حساسية العين تجاه الضوء.</li><li>برودة مفاجأة مع إغماء أو ضعف أو هبوط.</li><li>صعوبة في التنفس مع صفير أو سعال.</li><li>شرى.</li></ul><p dir="RTL"><strong>نادرة (قد تؤثر فيما يصل إلى شخص من بين كل 1000 شخص):</strong></p><ul dir="rtl"><li>بطء نبضات القلب.</li><li>ارتباك.</li><li>نادراً ما قد يحدث كسر غير عادي لعظام الفخذ خصوصاً لدى المرضى الذي يتلقون علاجاً طويل المدى لهشاشة العظام. اتصل على طبيبك إذا عانيت من ألم، ضعف أو عدم ارتياح في الفخذ، الورك أو الأربية نظراً إلى أن ذلك قد يكون مؤشراً مبكراً لكسر محتمل لعظام الفخذ.</li><li>مرض الرئة الخلالي (التهاب الأنسجة حول الأكياس الهوائية للرئتين)</li><li>أعراض تشبه أعراض الأنفلونزا تشمل التهاب وتورم المفاصل.</li><li>احمرار و/أو تورم مؤلم للعين.</li></ul><p dir="RTL"><strong>نادرة جداً (قد تؤثر فيما يصل إلى شخص من بين كل 10000 شخص): </strong></p><ul dir="rtl"><li>إغماء بسبب انخفاض ضغط الدم.</li><li>ألم شديد في العظام والمفاصل و/أو العضلات يسبب العجز أحياناً.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 30&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية.</p><p dir="RTL">بعد التخفيف: يجب استخدام المحلول المخفف للتسريب على الفور لتجنب التلوث المیكروبيّ. في حال عدم الاستخدام على الفور، تقع مسؤولية فترات التخزين أثناء الاستخدام وظروف التخزين قبل الاستخدام على المستخدم ويجب ألا تزيد عادة عن 24 ساعة عند درجات حرارة تتراوح من 2-8&deg; مئوية.</p><p dir="RTL">يجب معادلة المحلول المخزن بالثلاجة لدرجة حرارة الغرفة قبل إعطائه.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعّالة هي حمض الزوليدرونيك أحادي الماء.</p><p dir="RTL">يحتوي كل 5 مللتر من زيدرونيك 4 ملغم/5 مللتر مركز للتخفيف للتسريب على 4.264 ملغم حمض الزوليدرونيك أحادي الماء يكافئ 4 ملغم حمض الزوليدرونيك اللامائي.</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي مانيتول، سيترات الصوديوم وماء معدّ للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">زيدرونيك 4 ملغم/5 مللتر مركز للتخفيف للتسريب هو محلول صافٍ وعديم اللون في زجاجات شفافة بحجم 5 مللتر من النوع رقم واحد محكمة الإغلاق بسدادات رمادية مطاطية من البيوتيل وأغطية زرقاء من الألومينيوم قابلة للفتح لأعلى.</p><p dir="RTL">حجم العبوة: زجاجة واحدة (5 مللتر).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق </strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL"><strong>الشركة المصنعة </strong></p><p dir="RTL">شركة أدوية الحكمة (البرتغال)، المساهمة العامة المحدودة<br />إسترادا دو ريو دا مو،</p><p dir="RTL">مبنى رقم &deg;8, 8A e 8B، فارفانسا<br />906-2705 تيروجيم</p><p dir="RTL">سنترا، البرتغال<br />هاتف: 19608410 (2-351) +<br />فاكس: 19615102 (2-351) +<br />&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><ul dir="rtl"><li>المملكة العربية السعودية</li></ul><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><ul dir="rtl"><li>دول الخليج العربي الأخرى</li></ul><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 01/2024، رقم النسخة: SA2.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zidronic 4 mg/5 ml Concentrate for Solution for Infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 5 ml contains 4.264 mg zoledronic acid monohydrate equivalent to 4 mg zoledronic acid anhydrous.

Excipient with known effect: Sodium.

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion.

Clear and colourless solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.</li><li>Treatment of adult patients with tumour-induced hypercalcaemia (TIH).</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zoledronic acid must only be prescribed and administered to patients by healthcare professionals experienced in the administration of intravenous bisphosphonates. Patients treated with zoledronic acid should be given the package leaflet.</p><p><strong>Posology</strong></p><p><u>Prevention of skeletal related events in patients with advanced malignancies involving bone</u></p><p><em>Adults and elderly</em></p><p>The recommended dose in the prevention of skeletal related events in patients with advanced malignancies involving bone is 4 mg zoledronic acid every 3 to 4 weeks.</p><p>Patients should also be administered an oral calcium supplement of 500 mg and 400 IU vitamin D daily.</p><p>The decision to treat patients with bone metastases for the prevention of skeletal related events should consider that the onset of treatment effect is 2-3 months.</p><p><u>Treatment of TIH</u></p><p><em>Adults and elderly</em></p><p>The recommended dose in hypercalcaemia (albumin-corrected serum calcium &ge;12.0 mg/dl or 3.0 mmol/l) is a single dose of 4 mg zoledronic acid.</p><p><em>Renal impairment</em></p><ul><li><em>TIH:</em></li></ul><p>Zoledronic acid treatment in TIH patients who also have severe renal impairment should be considered only after evaluating the risks and benefits of treatment. In the clinical studies, patients with serum creatinine &gt; 400 &micro;mol/l or &gt; 4.5 mg/dl were excluded. No dose adjustment is necessary in TIH patients with serum creatinine &lt; 400 &micro;mol/l or &lt; 4.5 mg/dl (see section 4.4).</p><p>&nbsp;</p><ul><li><em>Prevention of skeletal related events in patients with advanced malignancies involving bone:</em></li></ul><p>When initiating treatment with zoledronic acid in patients with multiple myeloma or metastatic bone lesions from solid tumours, serum creatinine and creatinine clearance (CLcr) should be determined. CLcr is calculated from serum creatinine using the Cockcroft-Gault formula.</p><p>Zoledronic acid is not recommended for patients presenting with severe renal impairment prior to initiation of therapy, which is defined for this population as CLcr &lt; 30 ml/min. In clinical trials with zoledronic acid, patients with serum creatinine &gt; 265 &micro;mol/l or &gt; 3.0 mg/dl were excluded.</p><p>In patients with bone metastases presenting with mild to moderate renal impairment prior to initiation of therapy, which is defined for this population as CLcr 30&ndash;60 ml/min, the following zoledronic acid dose is recommended (see also section 4.4):</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Baseline creatinine clearance (ml/min)</strong></p></td><td style="vertical-align:top"><p><strong>Zoledronic Acid Recommended Dose*</strong></p></td></tr><tr><td style="vertical-align:top"><p>&gt; 60</p></td><td style="vertical-align:top"><p>4.0 mg zoledronic acid</p></td></tr><tr><td style="vertical-align:top"><p>50&ndash;60</p></td><td style="vertical-align:top"><p>3.5 mg* zoledronic acid</p></td></tr><tr><td style="vertical-align:top"><p>40&ndash;49</p></td><td style="vertical-align:top"><p>3.3 mg* zoledronic acid</p></td></tr><tr><td style="vertical-align:top"><p>30&ndash;39</p></td><td style="vertical-align:top"><p>3.0 mg* zoledronic acid</p></td></tr></tbody></table><p><strong>*</strong>Doses have been calculated assuming target AUC of 0.66 (mg&bull;hr/l) (CLcr=75 ml/min). The reduced doses for patients with renal impairment are expected to achieve the same AUC as that seen in patients with creatinine clearance of 75 ml/min.</p><p>Following initiation of therapy, serum creatinine should be measured prior to each dose of zoledronic acid and treatment should be withheld if renal function has deteriorated. In the clinical trials, renal deterioration was defined as follows:</p><ul><li>For patients with normal baseline serum creatinine (&lt; 1.4 mg/dl or &lt; 124 &micro;mol/l), an increase of 0.5 mg/dl or 44 &micro;mol/l;</li><li>For patients with abnormal baseline creatinine (&gt; 1.4 mg/dl or &gt; 124 &micro;mol/l), an increase of 1.0 mg/dl or 88 &micro;mol/l.</li></ul><p>In the clinical studies, zoledronic acid treatment was resumed only when the creatinine level returned to within 10% of the baseline value (see section 4.4). Zoledronic acid treatment should be resumed at the same dose as that given prior to treatment interruption.</p><p><em>Paediatric population</em></p><p>The safety and efficacy of zoledronic acid in children aged 1 year to 17 years have not been established. Currently available data are described in section 5.1 but no recommendation on a posology can be made.</p><p><strong>Method of administration</strong></p><p>Intravenous use.</p><p>Zidronic, further diluted in 100 ml (see section 6.6), should be given as a single intravenous infusion in no less than 15 minutes.</p><p>In patients with mild to moderate renal impairment, reduced zoledronic acid doses are recommended (see section &ldquo;Posology&rdquo; above and section 4.4).</p><p><u>Instructions for preparing reduced doses of Zidronic</u></p><p>Withdraw an appropriate volume of the concentrate needed, as follows:</p><ul><li>4.4 ml for 3.5 mg dose</li><li>4.1 ml for 3.3 mg dose</li><li>3.8 ml for 3.0 mg dose</li></ul><p>For instructions on the dilution of the medicinal product before administration, see section 6.6. The withdrawn amount of concentrate must be further diluted in 100 ml of 9 mg/ml (0.9%) sodium chloride solution for injection or 5% w/v glucose solution. The dose must be given as a single intravenous infusion over no less than 15 minutes.</p><p>Zidronic concentrate must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer&#39;s solution, and should be administered as a single intravenous solution in a separate infusion line.</p><p>Patients must be maintained well hydrated prior to and following administration of Zidronic</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substance, to other bisphosphonates or to any of the excipients listed in section 6.1.
• Breast-feeding (see section 4.6).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General</u></p><p>Patients must be assessed prior to administration of zoledronic acid to ensure that they are adequately hydrated.</p><p>Overhydration should be avoided in patients at risk of cardiac failure.</p><p>Standard hypercalcaemia-related metabolic parameters, such as serum levels of calcium, phosphate and magnesium, should be carefully monitored after initiating zoledronic acid therapy. If hypocalcaemia, hypophosphataemia, or hypomagnesaemia occurs, short-term supplemental therapy may be necessary. Untreated hypercalcaemia patients generally have some degree of renal function impairment, therefore careful renal function monitoring should be considered.</p><p>Other products containing zoledronic acid as active substance are available for osteoporosis indications and treatment of Paget&acute;s disease of the bone. Patients being treated with Zidronic should not be treated with such products or any other bisphosphonate concomitantly, since the combined effects of these agents are unknown.</p><p><u>Zidronic contains sodium</u></p><p>Zidronic contains sodium. Each 5 ml contains 6.417 mg sodium. This medicine contains less than 1 mmol sodium (23 mg) per 5 ml, that is to say essentially &lsquo;sodium-free&rsquo;.<strong> </strong></p><p><u>Renal insufficiency</u></p><p>Patients with TIH and evidence of deterioration in renal function should be appropriately evaluated with consideration given as to whether the potential benefit of treatment with zoledronic acid outweighs the possible risk.</p><p>The decision to treat patients with bone metastases for the prevention of skeletal related events should consider that the onset of treatment effect is 2-3 months.</p><p>Zoledronic acid has been associated with reports of renal dysfunction. Factors that may increase the potential for deterioration in renal function include dehydration, pre-existing renal impairment, multiple cycles of zoledronic acid and other bisphosphonates as well as use of other nephrotoxic medicinal products. While the risk is reduced with a dose of 4 mg zoledronic acid administered over 15 minutes, deterioration in renal function may still occur. Renal deterioration, progression to renal failure and dialysis have been reported in patients after the initial dose or a single dose of 4 mg zoledronic acid. Increases in serum creatinine also occur in some patients with chronic administration of zoledronic acid at recommended doses for prevention of skeletal related events, although less frequently.</p><p>Patients should have their serum creatinine levels assessed prior to each dose of zoledronic acid. Upon initiation of treatment in patients with bone metastases with mild to moderate renal impairment, lower doses of zoledronic acid are recommended. In patients who show evidence of renal deterioration during treatment, zoledronic acid should be withheld. Zoledronic acid should only be resumed when serum creatinine returns to within 10% of baseline. Zoledronic acid treatment should be resumed at the same dose as that given prior to treatment interruption.</p><p>In view of the potential impact of zoledronic acid on renal function, the lack of clinical safety data in patients with severe renal impairment (in clinical trials defined as serum creatinine &ge;400 &micro;mol/l or &ge;4.5 mg/dl for patients with TIH and &ge;265 &micro;mol/l or &ge;3.0 mg/dl for patients with cancer and bone metastases, respectively) at baseline and only limited pharmacokinetic data in patients with severe renal impairment at baseline (creatinine clearance &lt; 30 ml/min), the use of zoledronic acid is not recommended in patients with severe renal impairment.</p><p><u>Hepatic insufficiency</u></p><p>As only limited clinical data are available in patients with severe hepatic insufficiency, no specific recommendations can be given for this patient population.</p><p><u>Osteonecrosis</u></p><p><em>Osteonecrosis of the jaw</em></p><p>Osteonecrosis of the jaw (ONJ) has been reported uncommonly in clinical trials in patients receiving zoledronic acid. Post-marketing experience and the literature suggest a greater frequency of reports of ONJ based on tumour type (advanced breast cancer, multiple myeloma). A study showed that ONJ was higher in myeloma patients when compared to other cancers (see section 5.1).</p><p>The start of treatment or of a new course of treatment should be delayed in patients with unhealed open soft tissue lesions in the mouth, except in medical emergency situations. A dental examination with appropriate preventive dentistry and an individual benefit-risk assessment is recommended prior to treatment with bisphosphonates in patients with concomitant risk factors.</p><p>The following risk factors should be considered when evaluating an individual&#39;s risk of developing ONJ:</p><ul><li>Potency of the bisphosphonate (higher risk for highly potent compounds), route of administration (higher risk for parenteral administration) and cumulative dose of bisphosphonate.</li><li>Cancer, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking.</li><li>Concomitant therapies: chemotherapy, angiogenesis inhibitors (see section 4.5), radiotherapy to neck and head, corticosteroids.</li><li>History of dental disease, poor oral hygiene, periodontal disease, invasive dental procedures (e.g. tooth extractions) and poorly fitting dentures.</li></ul><p>All patients should be encouraged to maintain good oral hygiene, undergo routine dental check-ups, and immediately report any oral symptoms such as dental mobility, pain or swelling, or non-healing of sores or discharge during treatment with zoledronic acid.</p><p>While on treatment, invasive dental procedures should be performed only after careful consideration and be avoided in close proximity to zoledronic acid administration. For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may exacerbate the condition. For patients requiring dental procedures, there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of osteonecrosis of the jaw. The management plan for patients who develop ONJ should be set up in close collaboration between the treating physician and a dentist or oral surgeon with expertise in ONJ. Temporary interruption of zoledronic acid treatment should be considered until the condition resolves and contributing risk factors are mitigated where possible.</p><p><em>Osteonecrosis of other anatomical sites</em></p><p>Osteonecrosis of the external auditory canal has been reported with bisphosphonates, mainly in association with long-term therapy. Possible risk factors for osteonecrosis of the external auditory canal include steroid use and chemotherapy and/or local risk factors such as infection or trauma. The possibility of osteonecrosis of the external auditory canal should be considered in patients receiving bisphosphonates who present with ear symptoms including chronic ear infections.</p><p>Additionally, there have been sporadic reports of osteonecrosis of other sites, including the hip and femur, reported predominantly in adult cancer patients treated with zoledronic acid.</p><p><u>Musculoskeletal pain</u></p><p>In post-marketing experience, severe and occasionally incapacitating bone, joint, and/or muscle pain have been reported in patients taking zoledronic acid. However, such reports have been infrequent. The time to onset of symptoms varied from one day to several months after starting treatment. Most patients had relief of symptoms after stopping treatment. A subset had recurrence of symptoms when rechallenged with zoledronic acid or another bisphosphonate.</p><p><u>Atypical fractures of the femur</u></p><p>Atypical subtrochanteric and diaphyseal femoral fractures have been reported with bisphosphonate therapy, primarily in patients receiving long-term treatment for osteoporosis. These transverse or short oblique fractures can occur anywhere along the femur from just below the lesser trochanter to just above the supracondylar flare. These fractures occur after minimal or no trauma and some patients experience thigh or groin pain, often associated with imaging features of stress fractures, weeks to months before presenting with a completed femoral fracture. Fractures are often bilateral; therefore, the contralateral femur should be examined in bisphosphonate-treated patients who have sustained a femoral shaft fracture. Poor healing of these fractures has also been reported. Discontinuation of bisphosphonate therapy in patients suspected to have an atypical femur fracture should be considered pending evaluation of the patient, based on an individual benefit risk assessment.</p><p>During bisphosphonate treatment patients should be advised to report any thigh, hip or groin pain and any patient presenting with such symptoms should be evaluated for an incomplete femur fracture.</p><p><u>Hypocalcaemia</u></p><p>Hypocalcaemia has been reported in patients treated with zoledronic acid. Cardiac arrhythmias and neurologic adverse events (including convulsions, hypoaesthesia and tetany) have been reported secondary to cases of severe hypocalcaemia. Cases of severe hypocalcaemia requiring hospitalisation have been reported. In some instances, the hypocalcaemia may be life-threatening (see section 4.8). Caution is advised when Zoledronic acid is administered with medicinal products known to cause hypocalcaemia, as they may have a synergistic effect resulting in severe hypocalcaemia (see section 4.5). Serum calcium should be measured and hypocalcaemia must be corrected before initiating zoledronic acid therapy. Patients should be adequately supplemented with calcium and vitamin D</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical studies, zoledronic acid has been administered concomitantly with commonly used anticancer agents, diuretics, antibiotics and analgesics without clinically apparent interactions occurring. Zoledronic acid shows no appreciable binding to plasma proteins and does not inhibit human P450 enzymes&nbsp;<em>in vitro</em>&nbsp;(see section 5.2), but no formal clinical interaction studies have been performed.</p><p>Caution is advised when bisphosphonates are administered with aminoglycosides, calcitonin or loop diuretics since these agents may have an additive effect, resulting in a lower serum calcium level for longer periods than required (see section 4.4).</p><p>Caution is indicated when zoledronic acid is used with other potentially nephrotoxic medicinal products. Attention should also be paid to the possibility of hypomagnesaemia developing during treatment.</p><p>In multiple myeloma patients, the risk of renal dysfunction may be increased when zoledronic acid is used in combination with thalidomide.</p><p>Caution is advised when zoledronic acid is administered with anti-angiogenic medicinal products as an increase in the incidence of ONJ has been observed in patients treated concomitantly with these medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no adequate data on the use of zoledronic acid in pregnant women. Animal reproduction studies with zoledronic acid have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Zoledronic acid should not be used during pregnancy. Women of child-bearing potential should be advised to avoid becoming pregnant.</p><p><u>Breast-feeding</u></p><p>It is not known whether zoledronic acid is excreted into human milk. Zoledronic acid is contraindicated in breast-feeding women (see section 4.3).</p><p><u>Fertility</u></p><p>Zoledronic acid was evaluated in rats for potential adverse effects on fertility of the parental and F1 generation. This resulted in exaggerated pharmacological effects considered to be related to the compound&#39;s inhibition of skeletal calcium metabolisation, resulting in periparturient hypocalcaemia, a bisphosphonate class effect, dystocia and early termination of the study. Thus these results precluded determining a definitive effect of zoledronic acid on fertility in humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions, such as dizziness and somnolence, may have influence on the ability to drive or use machines, therefore caution should be exercised with the use of zoledronic acid along with driving and operating of machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>Within three days after zoledronic acid administration, an acute phase reaction has commonly been reported, with symptoms including bone pain, fever, fatigue, arthralgia, myalgia, rigors and arthritis with subsequent joint swelling; these symptoms usually resolve within a few days (see description of selected adverse reactions).</p><p>The following are the important identified risks with zoledronic acid in the approved indications:</p><p>Renal function impairment, osteonecrosis of the jaw, acute phase reaction, hypocalcaemia, atrial fibrillation, anaphylaxis, interstitial lung disease. The frequencies for each of these identified risks are shown in Table 1.</p><p><u>Tabulated list of adverse reactions</u></p><p>The following adverse reactions, listed in Table 1, have been accumulated from clinical studies and post-marketing reports following predominantly chronic treatment with 4 mg zoledronic acid:</p><p>Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p><strong>Table 1</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:761px"><tbody><tr><td colspan="2" style="vertical-align:top; width:758px"><p><strong><em>Blood and lymphatic system disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top; width:621px"><p>Anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top; width:621px"><p>Thrombocytopenia, leukopenia</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top; width:621px"><p>Pancytopenia</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:758px"><p><strong><em>Immune system disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top; width:621px"><p>Hypersensitivity reaction</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top; width:621px"><p>Angioneurotic oedema</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:758px"><p><strong><em>Psychiatric disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top; width:621px"><p>Anxiety, sleep disturbance</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top; width:621px"><p>Confusion</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:758px"><p><strong><em>Nervous system disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top; width:621px"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top; width:621px"><p>Dizziness, paraesthesia, dysgusia, hypoaesthesia, hyperaesthesia, tremor, somnolence</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top; width:621px"><p>Convulsions, hypoaesthesia and tetany (secondary to hypocalcaemia)</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:758px"><p><strong><em>Eye disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top; width:621px"><p>Conjunctivitis</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top; width:621px"><p>Blurred vision, scleritis and orbital inflammation</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top; width:621px"><p>Uveitis</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top; width:621px"><p>Episcleritis</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:758px"><p><strong><em>Cardiac disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top; width:621px"><p>Hypertension, hypotension, atrial fibrillation, hypotension leading to syncope or circulatory collapse</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top; width:621px"><p>Bradycardia, cardiac arrhythmia (secondary to hypocalcaemia)</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:758px"><p><strong><em>Respiratory, thoracic and mediastinal disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top; width:621px"><p>Dyspnoea, cough, bronchoconstriction</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top; width:621px"><p>Interstitial lung disease</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:758px"><p><strong><em>Gastrointestinal disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top; width:621px"><p>Nausea, vomiting, decreased appetite</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top; width:621px"><p>Diarrhoea, constipation, abdominal pain, dyspepsia, stomatitis, dry mouth</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:758px"><p><strong><em>Skin and subcutaneous tissue disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top; width:621px"><p>Pruritus, rash (including erythematous and macular rash), increased sweating</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:758px"><p><strong><em>Musculoskeletal and connective tissue disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top; width:621px"><p>Bone pain, myalgia, arthralgia, generalised pain</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top; width:621px"><p>Muscle spasms, osteonecrosis of the jaw</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top; width:621px"><p>Osteonecrosis of the external auditory canal (bisphosphonate class adverse reaction)&nbsp;<u>and other anatomical sites including femur and hip</u></p></td></tr><tr><td colspan="2" style="vertical-align:top; width:758px"><p><strong><em>Renal and urinary disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top; width:621px"><p>Renal impairment</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top; width:621px"><p>Acute renal failure, haematuria, proteinuria</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top; width:621px"><p>Acquired Fanconi syndrome</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:758px"><p><strong><em>General disorders and administration site conditions</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top; width:621px"><p>Fever, flu-like syndrome (including fatigue, rigors, malaise and flushing)</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top; width:621px"><p>Asthenia, peripheral oedema, injection site reactions (including pain, irritation, swelling, induration), chest pain, weight increase, anaphylactic reaction/shock, urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top; width:621px"><p>Arthritis and joint swelling as a symptom of acute phase reaction</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:758px"><p><strong><em>Investigations</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top; width:621px"><p>Hypophosphataemia</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top; width:621px"><p>Blood creatinine and blood urea increased, hypocalcaemia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top; width:621px"><p>Hypomagnesaemia, hypokalaemia</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top; width:621px"><p>Hyperkalaemia, hypernatraemia</p></td></tr></tbody></table><p><u>Description of selected adverse reactions</u></p><p><em>Renal function impairment</em></p><p>Zoledronic acid has been associated with reports of renal dysfunction. In a pooled analysis of safety data from zoledronic acid registration trials for the prevention of skeletal-related events in patients with advanced malignancies involving bone, the frequency of renal impairment adverse events suspected to be related to zoledronic acid (adverse reactions) was as follows: multiple myeloma (3.2%), prostate cancer (3.1%), breast cancer (4.3%), lung and other solid tumours (3.2%). Factors that may increase the potential for deterioration in renal function include dehydration, pre-existing renal impairment, multiple cycles of zoledronic acid or other bisphosphonates, as well as concomitant use of nephrotoxic medicinal products or using a shorter infusion time than currently recommended. Renal deterioration, progression to renal failure and dialysis have been reported in patients after the initial dose or a single dose of 4 mg zoledronic acid (see section 4.4).</p><p><em>Osteonecrosis of the jaw</em></p><p>Cases of osteonecrosis of the jaw have been reported, predominantly in cancer patients treated with medicinal products that inhibit bone resorption, such as zoledronic acid (see section 4.4). Many of these patients were also receiving chemotherapy and corticosteroids and had signs of local infection including osteomyelitis. The majority of the reports refer to cancer patients following tooth extractions or other dental surgeries.</p><p><em>Atrial fibrillation</em></p><p>In one 3-year, randomised, double-blind controlled trial that evaluated the efficacy and safety of zoledronic acid 5 mg once yearly vs. placebo in the treatment of postmenopausal osteoporosis (PMO), the overall incidence of atrial fibrillation was 2.5% (96 out of 3,862) and 1.9% (75 out of 3,852) in patients receiving zoledronic acid 5 mg and placebo, respectively. The rate of atrial fibrillation serious adverse events was 1.3% (51 out of 3,862) and 0.6% (22 out of 3,852) in patients receiving zoledronic acid 5 mg and placebo, respectively. The imbalance observed in this trial has not been observed in other trials with zoledronic acid, including those with zoledronic acid 4 mg every 3-4 weeks in oncology patients. The mechanism behind the increased incidence of atrial fibrillation in this single clinical trial is unknown.</p><p><em>Acute phase reaction</em></p><p>This adverse drug reaction consists of a constellation of symptoms that includes fever, myalgia, headache, extremity pain, nausea, vomiting, diarrhoea, arthralgia and arthritis with subsequent joint swelling. The onset time is &le;3 days post-zoledronic acid infusion, and the reaction is also referred to using the terms &ldquo;flu-like&rdquo; or &ldquo;post-dose&rdquo; symptoms.</p><p><em>Atypical fractures of the femur</em></p><p>During post-marketing experience the following reactions have been reported (frequency rare):</p><p>Atypical subtrochanteric and diaphyseal femoral fractures (bisphosphonate class adverse reaction).</p><p><em>Hypocalcaemia-related ADRs</em></p><p>Hypocalcaemia is an important identified risk with zoledronic acid in the approved indications. Based on the review of both clinical trial and post-marketing cases, there is sufficient evidence to support an association between zoledronic acid therapy, the reported event of hypocalcaemia, and the secondary development of cardiac arrhythmia. Furthermore, there is evidence of an association between hypocalcaemia and secondary neurological events reported in these cases including; convulsions, hypoaesthesia and tetany (see section 4.4).</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&middot;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp; Other GCC States</p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical experience with acute overdose of zoledronic acid is limited. The administration of doses up to 48 mg of zoledronic acid in error has been reported. Patients who have received doses higher than those recommended (see section 4.2) should be carefully monitored, since renal function impairment (including renal failure) and serum electrolyte (including calcium, phosphorus and magnesium) abnormalities have been observed. In the event of hypocalcaemia, calcium gluconate infusions should be administered as clinically indicated.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Medicinal products for treatment of bone diseases, bisphosphonates, ATC code: M05BA08</p><p>Zoledronic acid belongs to the class of bisphosphonates and acts primarily on bone. It is an inhibitor of osteoclastic bone resorption.</p><p>The selective action of bisphosphonates on bone is based on their high affinity for mineralised bone, but the precise molecular mechanism leading to the inhibition of osteoclastic activity is still unclear. In long-term animal studies, zoledronic acid inhibits bone resorption without adversely affecting the formation, mineralisation or mechanical properties of bone.</p><p>In addition to being a potent inhibitor of bone resorption, zoledronic acid also possesses several anti-tumour properties that could contribute to its overall efficacy in the treatment of metastatic bone disease. The following properties have been demonstrated in preclinical studies:</p><ul><li><em>In vivo:</em>&nbsp;Inhibition of osteoclastic bone resorption, which alters the bone marrow microenvironment, making it less conducive to tumour cell growth, anti-angiogenic activity and anti-pain activity.</li><li>&middot;<em>In vitro:&nbsp;</em>Inhibition of osteoblast proliferation, direct cytostatic and pro-apoptotic activity on tumour cells, synergistic cytostatic effect with other anti-cancer medicinal products, anti-adhesion/invasion activity.</li></ul><p><u>Clinical trial results in the prevention of skeletal related events in patients with advanced malignancies involving bone</u></p><p>The first randomised, double-blind, placebo-controlled study compared zoledronic acid 4 mg to placebo for the prevention of skeletal related events (SREs) in prostate cancer patients. Zoledronic acid 4 mg significantly reduced the proportion of patients experiencing at least one skeletal related event (SRE), delayed the median time to first SRE by &gt; 5 months, and reduced the annual incidence of events per patient - skeletal morbidity rate. Multiple event analysis showed a 36% risk reduction in developing SREs in the zoledronic acid 4 mg group compared with placebo. Patients receiving zoledronic acid 4 mg reported less increase in pain than those receiving placebo, and the difference reached significance at months 3, 9, 21 and 24. Fewer zoledronic acid 4 mg patients suffered pathological fractures. The treatment effects were less pronounced in patients with blastic lesions. Efficacy results are provided in Table 2.</p><p>In a second study including solid tumours other than breast or prostate cancer, zoledronic acid 4 mg significantly reduced the proportion of patients with an SRE, delayed the median time to first SRE by &gt; 2 months, and reduced the skeletal morbidity rate. Multiple event analysis showed 30.7% risk reduction in developing SREs in the zoledronic acid 4 mg group compared with placebo. Efficacy results are provided in Table 3.</p><table border="1" cellspacing="0" cellpadding="0" style="width:932px"><tbody><tr><td colspan="7" style="vertical-align:top; width:929px"><p><strong>Table 2:</strong>&nbsp;Efficacy results (prostate cancer patients receiving hormonal therapy)</p></td></tr><tr><td style="vertical-align:top; width:323px">&nbsp;</td><td colspan="2" style="vertical-align:top; width:196px"><p><u>Any SRE (+TIH)</u></p></td><td colspan="2" style="vertical-align:top; width:223px"><p><u>Fractures*</u></p></td><td colspan="2" style="vertical-align:top; width:187px"><p><u>Radiation therapy to bone</u></p></td></tr><tr><td style="vertical-align:top; width:323px">&nbsp;</td><td style="vertical-align:top; width:111px"><p>zoledronic acid</p><p>4 mg</p></td><td style="vertical-align:top; width:85px"><p>Placebo</p></td><td style="vertical-align:top; width:107px"><p>zoledronic acid</p><p>4 mg</p></td><td style="vertical-align:top; width:116px"><p>Placebo</p></td><td style="vertical-align:top; width:108px"><p>zoledronic acid</p><p>4 mg</p></td><td style="vertical-align:top; width:79px"><p>Placebo</p></td></tr><tr><td style="vertical-align:top; width:323px"><p>N</p></td><td style="vertical-align:top; width:111px"><p>214</p></td><td style="vertical-align:top; width:85px"><p>208</p></td><td style="vertical-align:top; width:107px"><p>214</p></td><td style="vertical-align:top; width:116px"><p>208</p></td><td style="vertical-align:top; width:108px"><p>214</p></td><td style="vertical-align:top; width:79px"><p>208</p></td></tr><tr><td style="vertical-align:top; width:323px"><p>Proportion of patients with SREs (%)</p></td><td style="vertical-align:top; width:111px"><p>38</p></td><td style="vertical-align:top; width:85px"><p>49</p></td><td style="vertical-align:top; width:107px"><p>17</p></td><td style="vertical-align:top; width:116px"><p>25</p></td><td style="vertical-align:top; width:108px"><p>26</p></td><td style="vertical-align:top; width:79px"><p>33</p></td></tr><tr><td style="vertical-align:top; width:323px"><p>p-value</p></td><td colspan="2" style="vertical-align:top; width:196px"><p>0.028</p></td><td colspan="2" style="vertical-align:top; width:223px"><p>0.052</p></td><td colspan="2" style="vertical-align:top; width:187px"><p>0.119</p></td></tr><tr><td style="vertical-align:top; width:323px"><p>Median time to SRE (days)</p></td><td style="vertical-align:top; width:111px"><p>488</p></td><td style="vertical-align:top; width:85px"><p>321</p></td><td style="vertical-align:top; width:107px"><p>NR</p></td><td style="vertical-align:top; width:116px"><p>NR</p></td><td style="vertical-align:top; width:108px"><p>NR</p></td><td style="vertical-align:top; width:79px"><p>640</p></td></tr><tr><td style="vertical-align:top; width:323px"><p>p-value</p></td><td colspan="2" style="vertical-align:top; width:196px"><p>0.009</p></td><td colspan="2" style="vertical-align:top; width:223px"><p>0.020</p></td><td colspan="2" style="vertical-align:top; width:187px"><p>0.055</p></td></tr><tr><td style="vertical-align:top; width:323px"><p>Skeletal morbidity rate</p></td><td style="vertical-align:top; width:111px"><p>0.77</p></td><td style="vertical-align:top; width:85px"><p>1.47</p></td><td style="vertical-align:top; width:107px"><p>0.20</p></td><td style="vertical-align:top; width:116px"><p>0.45</p></td><td style="vertical-align:top; width:108px"><p>0.42</p></td><td style="vertical-align:top; width:79px"><p>0.89</p></td></tr><tr><td style="vertical-align:top; width:323px"><p>p-value</p></td><td colspan="2" style="vertical-align:top; width:196px"><p>0.005</p></td><td colspan="2" style="vertical-align:top; width:223px"><p>0.023</p></td><td colspan="2" style="vertical-align:top; width:187px"><p>0.060</p></td></tr><tr><td style="vertical-align:top; width:323px"><p>Risk reduction of suffering from multiple events** (%)</p></td><td style="vertical-align:top; width:111px"><p>36</p></td><td style="vertical-align:top; width:85px"><p>-</p></td><td style="vertical-align:top; width:107px"><p>NA</p></td><td style="vertical-align:top; width:116px"><p>NA</p></td><td style="vertical-align:top; width:108px"><p>NA</p></td><td style="vertical-align:top; width:79px"><p>NA</p></td></tr><tr><td style="vertical-align:top; width:323px"><p>p-value</p></td><td colspan="2" style="vertical-align:top; width:196px"><p>0.002</p></td><td colspan="2" style="vertical-align:top; width:223px"><p>NA</p></td><td colspan="2" style="vertical-align:top; width:187px"><p>NA</p></td></tr></tbody></table><p>* Includes vertebral and non-vertebral fractures</p><p>** Accounts for all skeletal events, the total number as well as time to each event during the trial</p><p>NR Not Reached</p><p>NA Not Applicable</p><table border="1" cellspacing="0" cellpadding="0" style="width:932px"><tbody><tr><td colspan="7" style="vertical-align:top; width:929px"><p><strong>Table 3:</strong>&nbsp;Efficacy results (solid tumours other than breast or prostate cancer)</p></td></tr><tr><td style="vertical-align:top; width:323px">&nbsp;</td><td colspan="2" style="vertical-align:top; width:215px"><p><u>Any SRE (+TIH)</u></p></td><td colspan="2" style="vertical-align:top; width:210px"><p><u>Fractures*</u></p></td><td colspan="2" style="vertical-align:top; width:177px"><p><u>Radiation therapy to bone</u></p></td></tr><tr><td style="vertical-align:top; width:323px">&nbsp;</td><td style="vertical-align:top; width:122px"><p>zoledronic acid</p><p>4 mg</p></td><td style="vertical-align:top; width:93px"><p>Placebo</p></td><td style="vertical-align:top; width:105px"><p>zoledronic acid</p><p>4 mg</p></td><td style="vertical-align:top; width:105px"><p>Placebo</p></td><td style="vertical-align:top; width:85px"><p>zoledronic acid</p><p>4 mg</p></td><td style="vertical-align:top; width:92px"><p>Placebo</p></td></tr><tr><td style="vertical-align:top; width:323px"><p>N</p></td><td style="vertical-align:top; width:122px"><p>257</p></td><td style="vertical-align:top; width:93px"><p>250</p></td><td style="vertical-align:top; width:105px"><p>257</p></td><td style="vertical-align:top; width:105px"><p>250</p></td><td style="vertical-align:top; width:85px"><p>257</p></td><td style="vertical-align:top; width:92px"><p>250</p></td></tr><tr><td style="vertical-align:top; width:323px"><p>Proportion of patients with SREs (%)</p></td><td style="vertical-align:top; width:122px"><p>39</p></td><td style="vertical-align:top; width:93px"><p>48</p></td><td style="vertical-align:top; width:105px"><p>16</p></td><td style="vertical-align:top; width:105px"><p>22</p></td><td style="vertical-align:top; width:85px"><p>29</p></td><td style="vertical-align:top; width:92px"><p>34</p></td></tr><tr><td style="vertical-align:top; width:323px"><p>p-value</p></td><td colspan="2" style="vertical-align:top; width:215px"><p>0.039</p></td><td colspan="2" style="vertical-align:top; width:210px"><p>0.064</p></td><td colspan="2" style="vertical-align:top; width:177px"><p>0.173</p></td></tr><tr><td style="vertical-align:top; width:323px"><p>Median time to SRE (days)</p></td><td style="vertical-align:top; width:122px"><p>236</p></td><td style="vertical-align:top; width:93px"><p>155</p></td><td style="vertical-align:top; width:105px"><p>NR</p></td><td style="vertical-align:top; width:105px"><p>NR</p></td><td style="vertical-align:top; width:85px"><p>424</p></td><td style="vertical-align:top; width:92px"><p>307</p></td></tr><tr><td style="vertical-align:top; width:323px"><p>p-value</p></td><td colspan="2" style="vertical-align:top; width:215px"><p>0.009</p></td><td colspan="2" style="vertical-align:top; width:210px"><p>0.020</p></td><td colspan="2" style="vertical-align:top; width:177px"><p>0.079</p></td></tr><tr><td style="vertical-align:top; width:323px"><p>Skeletal morbidity rate</p></td><td style="vertical-align:top; width:122px"><p>1.74</p></td><td style="vertical-align:top; width:93px"><p>2.71</p></td><td style="vertical-align:top; width:105px"><p>0.39</p></td><td style="vertical-align:top; width:105px"><p>0.63</p></td><td style="vertical-align:top; width:85px"><p>1.24</p></td><td style="vertical-align:top; width:92px"><p>1.89</p></td></tr><tr><td style="vertical-align:top; width:323px"><p>p-value</p></td><td colspan="2" style="vertical-align:top; width:215px"><p>0.012</p></td><td colspan="2" style="vertical-align:top; width:210px"><p>0.066</p></td><td colspan="2" style="vertical-align:top; width:177px"><p>0.099</p></td></tr><tr><td style="vertical-align:top; width:323px"><p>Risk reduction of suffering from multiple events** (%)</p></td><td style="vertical-align:top; width:122px"><p>30.7</p></td><td style="vertical-align:top; width:93px"><p>-</p></td><td style="vertical-align:top; width:105px"><p>NA</p></td><td style="vertical-align:top; width:105px"><p>NA</p></td><td style="vertical-align:top; width:85px"><p>NA</p></td><td style="vertical-align:top; width:92px"><p>NA</p></td></tr><tr><td style="vertical-align:top; width:323px"><p>p-value</p></td><td colspan="2" style="vertical-align:top; width:215px"><p>0.003</p></td><td colspan="2" style="vertical-align:top; width:210px"><p>NA</p></td><td colspan="2" style="vertical-align:top; width:177px"><p>NA</p></td></tr></tbody></table><p>* Includes vertebral and non-vertebral fractures</p><p>** Accounts for all skeletal events, the total number as well as time to each event during the trial</p><p>NR Not Reached</p><p>NA Not Applicable</p><p>In a third phase III randomised, double-blind trial, zoledronic acid 4 mg or 90 mg pamidronate every 3 to 4 weeks were compared in patients with multiple myeloma or breast cancer with at least one bone lesion. The results demonstrated that zoledronic acid 4 mg showed comparable efficacy to 90 mg pamidronate in the prevention of SREs. The multiple event analysis revealed a significant risk reduction of 16% in patients treated with zoledronic acid 4 mg in comparison with patients receiving pamidronate. Efficacy results are provided in Table 4.</p><table border="1" cellspacing="0" cellpadding="0" style="width:924px"><tbody><tr><td colspan="7" style="vertical-align:top; width:921px"><p><strong>Table 4:&nbsp;</strong>Efficacy results (breast cancer and multiple myeloma patients)</p></td></tr><tr><td style="vertical-align:top; width:321px">&nbsp;</td><td colspan="2" style="vertical-align:top; width:224px"><p><u>Any SRE (+TIH)</u></p></td><td colspan="2" style="vertical-align:top; width:202px"><p><u>Fractures*</u></p></td><td colspan="2" style="vertical-align:top; width:196px"><p><u>Radiation therapy to bone</u></p></td></tr><tr><td style="vertical-align:top; width:321px">&nbsp;</td><td style="vertical-align:top; width:116px"><p>zoledronic acid 4 mg</p></td><td style="vertical-align:top; width:108px"><p>Pam 90 mg</p></td><td style="vertical-align:top; width:110px"><p>zoledronic acid</p><p>4 mg</p></td><td style="vertical-align:top; width:92px"><p>Pam 90 mg</p></td><td style="vertical-align:top; width:106px"><p>zoledronic acid</p><p>4 mg</p></td><td style="vertical-align:top; width:91px"><p>Pam 90 mg</p></td></tr><tr><td style="vertical-align:top; width:321px"><p>N</p></td><td style="vertical-align:top; width:116px"><p>561</p></td><td style="vertical-align:top; width:108px"><p>555</p></td><td style="vertical-align:top; width:110px"><p>561</p></td><td style="vertical-align:top; width:92px"><p>555</p></td><td style="vertical-align:top; width:106px"><p>561</p></td><td style="vertical-align:top; width:91px"><p>555</p></td></tr><tr><td style="vertical-align:top; width:321px"><p>Proportion of patients with SREs (%)</p></td><td style="vertical-align:top; width:116px"><p>48</p></td><td style="vertical-align:top; width:108px"><p>52</p></td><td style="vertical-align:top; width:110px"><p>37</p></td><td style="vertical-align:top; width:92px"><p>39</p></td><td style="vertical-align:top; width:106px"><p>19</p></td><td style="vertical-align:top; width:91px"><p>24</p></td></tr><tr><td style="vertical-align:top; width:321px"><p>p-value</p></td><td colspan="2" style="vertical-align:top; width:224px"><p>0.198</p></td><td colspan="2" style="vertical-align:top; width:202px"><p>0.653</p></td><td colspan="2" style="vertical-align:top; width:196px"><p>0.037</p></td></tr><tr><td style="vertical-align:top; width:321px"><p>Median time to SRE (days)</p></td><td style="vertical-align:top; width:116px"><p>376</p></td><td style="vertical-align:top; width:108px"><p>356</p></td><td style="vertical-align:top; width:110px"><p>NR</p></td><td style="vertical-align:top; width:92px"><p>714</p></td><td style="vertical-align:top; width:106px"><p>NR</p></td><td style="vertical-align:top; width:91px"><p>NR</p></td></tr><tr><td style="vertical-align:top; width:321px"><p>p-value</p></td><td colspan="2" style="vertical-align:top; width:224px"><p>0.151</p></td><td colspan="2" style="vertical-align:top; width:202px"><p>0.672</p></td><td colspan="2" style="vertical-align:top; width:196px"><p>0.026</p></td></tr><tr><td style="vertical-align:top; width:321px"><p>Skeletal morbidity rate</p></td><td style="vertical-align:top; width:116px"><p>1.04</p></td><td style="vertical-align:top; width:108px"><p>1.39</p></td><td style="vertical-align:top; width:110px"><p>0.53</p></td><td style="vertical-align:top; width:92px"><p>0.60</p></td><td style="vertical-align:top; width:106px"><p>0.47</p></td><td style="vertical-align:top; width:91px"><p>0.71</p></td></tr><tr><td style="vertical-align:top; width:321px"><p>p-value</p></td><td colspan="2" style="vertical-align:top; width:224px"><p>0.084</p></td><td colspan="2" style="vertical-align:top; width:202px"><p>0.614</p></td><td colspan="2" style="vertical-align:top; width:196px"><p>0.015</p></td></tr><tr><td style="vertical-align:top; width:321px"><p>Risk reduction of suffering from multiple events** (%)</p></td><td style="vertical-align:top; width:116px"><p>16</p></td><td style="vertical-align:top; width:108px"><p>-</p></td><td style="vertical-align:top; width:110px"><p>NA</p></td><td style="vertical-align:top; width:92px"><p>NA</p></td><td style="vertical-align:top; width:106px"><p>NA</p></td><td style="vertical-align:top; width:91px"><p>NA</p></td></tr><tr><td style="vertical-align:top; width:321px"><p>p-value</p></td><td colspan="2" style="vertical-align:top; width:224px"><p>0.030</p></td><td colspan="2" style="vertical-align:top; width:202px"><p>NA</p></td><td colspan="2" style="vertical-align:top; width:196px"><p>NA</p></td></tr></tbody></table><p>* Includes vertebral and non-vertebral fractures</p><p>** Accounts for all skeletal events, the total number as well as time to each event during the trial</p><p>NR Not Reached</p><p>NA Not Applicable</p><p>Zoledronic acid 4 mg was also studied in a double-blind, randomised, placebo-controlled trial in 228 patients with documented bone metastases from breast cancer to evaluate the effect of 4 mg zoledronic acid on the skeletal related event (SRE) rate ratio, calculated as the total number of SRE events (excluding hypercalcaemia and adjusted for prior fracture), divided by the total risk period. Patients received either 4 mg zoledronic acid or placebo every four weeks for one year. Patients were evenly distributed between zoledronic acid -treated and placebo groups.</p><p>The SRE rate (events/person year) was 0.628 for zoledronic acid and 1.096 for placebo. The proportion of patients with at least one SRE (excluding hypercalcaemia) was 29.8% in the zoledronic acid -treated group versus 49.6% in the placebo group (p=0.003). Median time to onset of the first SRE was not reached in the zoledronic acid -treated arm at the end of the study and was significantly prolonged compared to placebo (p=0.007). Zoledronic acid 4 mg reduced the risk of SREs by 41% in a multiple event analysis (risk ratio=0.59, p=0.019) compared with placebo.</p><p>In the zoledronic acid -treated group, statistically significant improvement in pain scores (using the Brief Pain Inventory, BPI) was seen at 4 weeks and at every subsequent time point during the study, when compared to placebo (Figure 1). The pain score for zoledronic acid was consistently below baseline and pain reduction was accompanied by a trend in reduced analgesics score.</p><p><strong>Figure 1: Mean changes from baseline in BPI scores. Statistically significant differences are marked (*p&lt;0.05) for between treatment comparisons (4 mg zoledronic acid vs. placebo)</strong></p><p><img src="data:image/png;base64,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" alt="" width="558" height="381" vspace="0" hspace="0" border="0" style="width:558px;height:381px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>CZOL446EUS122/SWOG study</p><p>The primary objective of this observational study was to estimate the cumulative incidence of osteonecrosis of the jaw (ONJ) at 3 years in cancer patients with bone metastasis receiving zoledronic acid. The osteoclast inhibition therapy, other cancer therapy, and dental care was performed as clinically indicated in order to best represent academic and community-based care. A baseline dental examination was recommended but was not mandatory.</p><p>Among the 3491 evaluable patients, 87 cases of ONJ diagnosis were confirmed. The overall estimated cumulative incidence of confirmed ONJ at 3 years was 2.8% (95% CI: 2.3-3.5%). The rates were 0.8% at year 1 and 2.0% at year 2. Rates of 3-year confirmed ONJ were highest in myeloma patients (4.3%) and lowest in breast cancer patients (2.4%). Cases of confirmed ONJ were statistically significantly higher in patients with multiple myeloma (p=0.03) than other cancers combined.</p><p><u>Clinical trial results in the treatment of TIH</u></p><p>Clinical studies in tumour-induced hypercalcaemia (TIH) demonstrated that the effect of zoledronic acid is characterised by decreases in serum calcium and urinary calcium excretion. In Phase I dose finding studies in patients with mild to moderate tumour-induced hypercalcaemia (TIH), effective doses tested were in the range of approximately 1.2&ndash;2.5 mg.</p><p>To assess the effects of 4 mg zoledronic acid versus pamidronate 90 mg, the results of two pivotal multicentre studies in patients with TIH were combined in a pre-planned analysis. There was faster normalisation of corrected serum calcium at day 4 for 8 mg zoledronic acid and at day 7 for 4 mg and 8 mg zoledronic acid. The following response rates were observed:</p><table border="1" cellspacing="0" cellpadding="0" style="width:666px"><tbody><tr><td colspan="4" style="vertical-align:top; width:663px"><p><strong>Table 5:</strong>&nbsp;Proportion of complete responders by day in the combined TIH studies</p></td></tr><tr><td style="vertical-align:top; width:199px">&nbsp;</td><td style="vertical-align:top; width:159px"><p>Day 4</p></td><td style="vertical-align:top; width:153px"><p>Day 7</p></td><td style="vertical-align:top; width:152px"><p>Day 10</p></td></tr><tr><td style="vertical-align:top; width:199px"><p>Zoledronic acid 4 mg (N=86)</p></td><td style="vertical-align:top; width:159px"><p>45.3% (p=0.104)</p></td><td style="vertical-align:top; width:153px"><p>82.6% (p=0.005)*</p></td><td style="vertical-align:top; width:152px"><p>88.4% (p=0.002)*</p></td></tr><tr><td style="vertical-align:top; width:199px"><p>Zoledronic acid 8 mg (N=90)</p></td><td style="vertical-align:top; width:159px"><p>55.6% (p=0.021)*</p></td><td style="vertical-align:top; width:153px"><p>83.3% (p=0.010)*</p></td><td style="vertical-align:top; width:152px"><p>86.7% (p=0.015)*</p></td></tr><tr><td style="vertical-align:top; width:199px"><p>Pamidronate 90 mg (N=99)</p></td><td style="vertical-align:top; width:159px"><p>33.3%</p></td><td style="vertical-align:top; width:153px"><p>63.6%</p></td><td style="vertical-align:top; width:152px"><p>69.7%</p></td></tr><tr><td colspan="4" style="vertical-align:top; width:663px"><p>*p-values compared to pamidronate.</p></td></tr></tbody></table><p>Median time to normocalcaemia was 4 days. Median time to relapse (re-increase of albumin-corrected serum calcium &ge;2.9 mmol/l) was 30 to 40 days for patients treated with zoledronic acid versus 17 days for those treated with pamidronate 90 mg (p-values: 0.001 for 4 mg and 0.007 for 8 mg zoledronic acid). There were no statistically significant differences between the two zoledronic acid doses.</p><p>In clinical trials 69 patients who relapsed or were refractory to initial treatment (zoledronic acid 4 mg, 8 mg or pamidronate 90 mg) were retreated with 8 mg zoledronic acid. The response rate in these patients was about 52%. Since those patients were retreated with the 8 mg dose only, there are no data available allowing comparison with the 4 mg zoledronic acid dose.</p><p>In clinical trials performed in patients with tumour-induced hypercalcaemia (TIH), the overall safety profile amongst all three treatment groups (zoledronic acid 4 and 8 mg and pamidronate 90 mg) was similar in types and severity.</p><p><u>Paediatric population</u></p><p><em>Clinical trial results in the treatment of severe osteogenesis imperfecta in paediatric patients aged 1 to 17 years</em></p><p>The effects of intravenous zoledronic acid in the treatment of paediatric patients (age 1 to 17 years) with severe osteogenesis imperfecta (types I, III and IV) were compared to intravenous pamidronate in one international, multicentre, randomised, open-label study with 74 and 76 patients in each treatment group, respectively. The study treatment period was 12 months preceded by a 4- to 9-week screening period during which vitamin D and elemental calcium supplements were taken for at least 2 weeks. In the clinical programme patients aged 1 to &lt; 3 years received 0.025 mg/kg zoledronic acid (up to a maximum single dose of 0.35 mg) every 3 months and patients aged 3 to 17 years received 0.05 mg/kg zoledronic acid (up to a maximum single dose of 0.83 mg) every 3 months. An extension study was conducted in order to examine the long-term general and renal safety of once yearly or twice yearly zoledronic acid over the 12-month extension treatment period in children who had completed one year of treatment with either zoledronic acid or pamidronate in the core study.</p><p>The primary endpoint of the study was the percent change from baseline in lumbar spine bone mineral density (BMD) after 12 months of treatment. Estimated treatment effects on BMD were similar, but the trial design was not sufficiently robust to establish non-inferior efficacy for zoledronic acid. In particular there was no clear evidence of efficacy on incidence of fracture or on pain. Fracture adverse events of long bones in the lower extremities were reported in approximately 24% (femur) and 14% (tibia) of zoledronic acid-treated patients vs 12% and 5% of pamidronate-treated patients with severe osteogenesis imperfecta, regardless of disease type and causality but overall incidence of fractures was comparable for the zoledronic acid and pamidronate-treated patients: 43% (32/74) vs 41% (31/76). Interpretation of the risk of fracture is confounded by the fact that fractures are common events in patients with severe osteogenesis imperfecta as part of the disease process.</p><p>The type of adverse reactions observed in this population were similar to those previously seen in adults with advanced malignancies involving the bone (see section 4.8). The adverse reactions ranked under headings of frequency, are presented in Table 6. The following conventional classification is used: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:661px"><tbody><tr><td colspan="2" style="vertical-align:top; width:658px"><p><strong>Table 6:</strong>&nbsp;Adverse reactions observed in paediatric patients with severe osteogenesis imperfecta<sup>1</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top; width:658px"><p><strong><em>Nervous system disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top; width:314px"><p>Headache</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:658px"><p><strong><em>Cardiac disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top; width:314px"><p>Tachycardia</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:658px"><p><strong><em>Respiratory, thoracic and mediastinal disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top; width:314px"><p>Nasopharyngitis</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:658px"><p><strong><em>Gastrointestinal disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top; width:314px"><p>Vomiting, nausea</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top; width:314px"><p>Abdominal pain</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:658px"><p><strong><em>Musculoskeletal and connective tissue disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top; width:314px"><p>Pain in extremities, arthralgia, musculoskeletal pain</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:658px"><p><strong><em>General disorders and administration site conditions</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top; width:314px"><p>Pyrexia, fatigue</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top; width:314px"><p>Acute phase reaction, pain</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:658px"><p><strong><em>Investigations</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top; width:314px"><p>Hypocalcaemia</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top; width:314px"><p>Hypophosphataemia</p></td></tr></tbody></table><p><sup>1</sup>&nbsp;Adverse events occurring with frequencies &lt; 5% were medically assessed and it was shown that these cases are consistent with the well established safety profile of zoledronic acid (see section 4.8)</p><p>&nbsp;</p><p>In paediatric patients with severe osteogenesis imperfecta, zoledronic acid seems to be associated with more pronounced risks for acute phase reaction, hypocalcaemia and unexplained tachycardia, in comparison to pamidronate, but this difference declined after subsequent infusions.</p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with zoledronic acid in all subsets of the paediatric population in the treatment of tumour-induced hypercalcaemia and prevention of skeletal-related events in patients with advanced malignancies involving bone (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single and multiple 5- and 15-minute infusions of 2, 4, 8 and 16 mg zoledronic acid in 64 patients with bone metastases yielded the following pharmacokinetic data, which were found to be dose independent.</p><p>After initiating the infusion of zoledronic acid, the plasma concentrations of zoledronic acid rapidly increased, achieving their peak at the end of the infusion period, followed by a rapid decline to &lt; 10% of peak after 4 hours and &lt; 1% of peak after 24 hours, with a subsequent prolonged period of very low concentrations not exceeding 0.1% of peak prior to the second infusion of zoledronic acid on day 28.</p><p>Intravenously administered zoledronic acid is eliminated by a triphasic process: rapid biphasic disappearance from the systemic circulation, with half-lives of t<sub>&frac12;&alpha;</sub>&nbsp;0.24 and t<sub>&frac12;&beta;</sub>&nbsp;1.87 hours, followed by a long elimination phase with a terminal elimination half-life of t<sub>&frac12;&gamma;</sub>&nbsp;146 hours. There was no accumulation of zoledronic acid in plasma after multiple doses given every 28 days. Zoledronic acid is not metabolised and is excreted unchanged via the kidney. Over the first 24 hours, 39 &plusmn; 16% of the administered dose is recovered in the urine, while the remainder is principally bound to bone tissue. From the bone tissue it is released very slowly back into the systemic circulation and eliminated via the kidney. The total body clearance is 5.04 &plusmn; 2.5 l/h, independent of dose, and unaffected by gender, age, race, and body weight. Increasing the infusion time from 5 to 15 minutes caused a 30% decrease in zoledronic acid concentration at the end of the infusion, but had no effect on the area under the plasma concentration versus time curve.</p><p>The interpatient variability in pharmacokinetic parameters for zoledronic acid was high, as seen with other bisphosphonates.</p><p>No pharmacokinetic data for zoledronic acid are available in patients with hypercalcaemia or in patients with hepatic insufficiency. Zoledronic acid does not inhibit human P450 enzymes&nbsp;<em>in vitro</em>, shows no biotransformation and in animal studies &lt; 3% of the administered dose was recovered in the faeces, suggesting no relevant role of liver function in the pharmacokinetics of zoledronic acid.</p><p>The renal clearance of zoledronic acid was correlated with creatinine clearance, renal clearance representing 75 &plusmn; 33% of the creatinine clearance, which showed a mean of 84 &plusmn; 29 ml/min (range 22 to 143 ml/min) in the 64 cancer patients studied. Population analysis showed that for a patient with creatinine clearance of 20 ml/min (severe renal impairment), or 50 ml/min (moderate impairment), the corresponding predicted clearance of zoledronic acid would be 37% or 72%, respectively, of that of a patient showing creatinine clearance of 84 ml/min. Only limited pharmacokinetic data are available in patients with severe renal insufficiency (creatinine clearance &lt; 30 ml/min).</p><p>In an in vitro study, zoledronic acid showed low affinity for the cellular components of human blood, with a mean blood to plasma concentration ratio of 0.59 in a concentration range of 30 ng/ml to 5000 ng/ml. The plasma protein binding is low, with the unbound fraction ranging from 60% at 2 ng/ml to 77% at 2000 ng/ml of zoledronic acid.</p><p><u>Special populations</u></p><p><em><u>Paediatric patients</u></em></p><p>Limited pharmacokinetic data in children with severe osteogenesis imperfecta suggest that zoledronic acid pharmacokinetics in children aged 3 to 17 years are similar to those in adults at a similar mg/kg dose level. Age, body weight, gender and creatinine clearance appear to have no effect on zoledronic acid systemic exposure.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Acute toxicity</u></p><p>The highest non-lethal single intravenous dose was 10 mg/kg bodyweight in mice and 0.6 mg/kg in rats.</p><p><u>Subchronic and chronic toxicity</u></p><p>Zoledronic acid was well tolerated when administered subcutaneously to rats and intravenously to dogs at doses up to 0.02 mg/kg daily for 4 weeks. Administration of 0.001 mg/kg/day subcutaneously in rats and 0.005 mg/kg intravenously once every 2&ndash;3 days in dogs for up to 52 weeks was also well tolerated.</p><p>The most frequent finding in repeat-dose studies consisted of increased primary spongiosa in the metaphyses of long bones in growing animals at nearly all doses, a finding that reflected the compound&#39;s pharmacological antiresorptive activity.</p><p>The safety margins relative to renal effects were narrow in the long-term repeat-dose parenteral animal studies but the cumulative no adverse event levels (NOAELs) in the single dose (1.6 mg/kg) and multiple dose studies of up to one month (0.06&ndash;0.6 mg/kg/day) did not indicate renal effects at doses equivalent to or exceeding the highest intended human therapeutic dose. Longer-term repeat administration at doses bracketing the highest intended human therapeutic dose of zoledronic acid produced toxicological effects in other organs, including the gastrointestinal tract, liver, spleen and lungs, and at intravenous injection sites.</p><p><u>Reproduction toxicity</u></p><p>Zoledronic acid was teratogenic in the rat at subcutaneous doses &ge;0.2 mg/kg. Although no teratogenicity or foetotoxicity was observed in the rabbit, maternal toxicity was found. Dystocia was observed at the lowest dose (0.01 mg/kg bodyweight) tested in the rat.</p><p><u>Mutagenicity and carcinogenic potential</u></p><p>Zoledronic acid was not mutagenic in the mutagenicity tests performed and carcinogenicity testing did not provide any evidence of carcinogenic potential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp; Mannitol</p><p>-&nbsp;&nbsp; Sodium citrate</p><p>-&nbsp;&nbsp; Water for injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>To avoid potential incompatibilities, Zidronic is to be diluted with 9 mg/ml (0.9%) sodium chloride solution for injection or 5% w/v glucose solution.</p><p>This medicinal product must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer&#39;s solution, and should be administered as a single intravenous solution in a separate infusion line.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months. 
After dilution: From a microbiological point of view, the diluted solution for infusion should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2-8°C. The refrigerated solution should then be equilibrated to room temperature prior to administration.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C. &nbsp;</p><p>Store in the original package.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5 ml type I clear glass vials sealed with butyl grey rubber stoppers and blue aluminum flip-off caps.</p><p>Pack size: 1 Vial (5 ml).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prior to administration, 5.0 ml concentrate from one vial or the volume of the concentrate withdrawn as required must be further diluted with 100 ml of calcium-free infusion solution (0.9% w/v sodium chloride solution or 5% w/v glucose solution).</p><p>Additional information on handling of Zidronic, including guidance on preparation of reduced doses, is provided in section 4.2.</p><p>Aseptic techniques must be followed during the preparation of the infusion. For single use only.</p><p>Only clear solution free from particles and discolouration should be used.</p><p>Healthcare professionals are advised not to dispose of unused Zidronic via the domestic sewage system.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. Box 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11 January 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>